Modifications in Systemic Rheumatic Disease Medications: Patients’ Perspectives During the Height of the COVID‐19 Pandemic in New York City

Abstract

Objective Concerns about severe acute respiratory syndrome coronavirus 2 (SARS–CoV‐2) infection may have led to changes or discontinuation of immunosuppressive medications among patients with systemic rheumatic disease. Our goal was to assess patients’ perspectives regarding medication modifications and deviations from planned uses during the height of the pandemic. Methods Adult patients of 13 rheumatologists at an academic center with physician‐diagnosed rheumatic disease and prescribed disease‐modifying medications were interviewed by telephone and asked open‐ended questions about the impact of SARS–CoV‐2 on their medications. Responses were analyzed using content and thematic analyses to generate categories that described patterns of medication modification. Results A total of 112 patients (mean age 50 years, 86% women, 34% non‐White race or Latino ethnicity) with diverse diagnoses (30% lupus, 26% rheumatoid arthritis, 44% other) who were taking various medications were enrolled. Patients reported clinically relevant issues that were iteratively reviewed to generate unique categories of medication modification: medications and increased or decreased risk of SARS–CoV‐2 infection; role of hydroxychloroquine; maintaining medication status quo; role of glucocorticoids; increasing or decreasing existing medications in relation to clinical disease activity; postponing infusions; and medication plan if infected by SARS–CoV‐2. Some modifications were suboptimal for disease control but were made to mitigate infection risk and to minimize potential harm when patients were unable to obtain laboratory tests and physical examinations due to cessation of in‐person office visits. Conclusion During the height of the pandemic, substantial medication modifications were made that, in some cases, were temporizing measures and deviations from planned regimens. Future studies will assess short‐ and long‐term sequelae of these medication modifications.

Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision

“…Reductions in DMARD use have been reported in other studies 17 19–22. Our results regarding 2020 suggest marked changes compared with 2019 (decreasing starts and increasing stops of bDMARDs/tsDMARDs); such changes in dispensations could be affected by treatment hoarding or prioritisation of use for COVID-19.…”

Evaluation of a Non-Face-to-Face Multidisciplinary Health Care Model in a Population with Rheumatoid Arthritis Vulnerable to COVID-19 in a Health Emergency Situation

“…Conversely, those who used the UC model exclusively, and those who transited between the models during the follow-up period had a significant adherence decrease measured through MGLS. Mancuso et al [ 42 ], showed that some medication modifications were suboptimal for disease control in rheumatological patients, but were made to mitigate infection risk and minimize potential harm when cessation of in-person office visits made laboratory tests and physical examinations unobtainable. The group of patients in our study who went from face-to-face to telemedicine may have decreased their adherence and methotrexate use due to the conditions contemplated by Mancuso et al Note that there was a significant increase in self-care among patients who had their first visit (TR model) or the entire follow-up in the face-to-face model, probably related to the fear of contracting the infection due to leaving their home.…”

Perceived Risk of SARS-CoV-2 at the Start of the COVID-19 Pandemic and Subsequent Vaccination Attitudes in Patients With Rheumatic Diseases

“…The enrollment period coincided with peak mortality rates due to the virus in New York City in April 2020. Patients were interviewed in depth with open-ended questions and standard surveys, and a rich tableau of the pandemic's adverse effects on personal, social, professional, emotional, and physical health was assembled 9–12 . Our plan was to track the clinical and personal impact of the unfolding pandemic longitudinally, and follow-up with patients at the time when a vaccine became available.…”